Fentanyl – A National Security Crisis Demanding Prevention

ARMR

Jennifer L

-

October 20, 2025

Fentanyl – A National Security Crisis Demanding Prevention

* Disseminated on behalf of ARMR Sciences Inc.
* For Accredited Investors Only. Offered pursuant to Rule 506(c). Reasonable steps to verify accreditation will be taken before any sale.
PAID ADVERTISEMENT – SPONSORED CONTENT

Fentanyl is no longer just another opioid – it has become the single most lethal synthetic drug in the United States. Since 2000, it is estimated that more than 20 million nonfatal overdoses have occurred in the U.S.- surpassing deaths from COVID-19, HIV/AIDS, and even major wars.

Today, fentanyl is the leading cause of death for adults aged 18–45, claiming an estimated 220 lives every single day.

A Silent, Rapid Killer

A minuscule amount – equivalent in size to just a few grains of salt – can be fatal. Fentanyl is fast-acting and often hidden in counterfeit pills or laced into drugs without the user’s knowledge.

Fentanyl is cheap to manufacture and covertly laced with counterfeit pills and recreational drugs. This stealth factor explains why the vast majority of overdose victims never intended to take fentanyl.

The financial toll is also staggering: the opioid epidemic costs the U.S. economy an estimated $2.7 trillion in 2023 alone, with cumulative losses exceeding $10 trillion over the past two decades.

Why Current Defenses Fall Short

Tools like naloxone (Narcan) have saved lives but remain purely reactive. They only work after an overdose begins and often fail against emerging analogs such as xylazine, nitazenes, or medetomidine, which Narcan cannot reverse. First responders, military personnel, and even families are left without effective long-term defenses.

ARMR’s Preventive Approach

ARMR Sciences is advancing its novel immunotherapy, ARMR-100, designed to train the immune system to block fentanyl before it reaches the brain. In preclinical (animal) studies, ARMR-100 blocked 92% of fentanyl’s entry into the brain and eliminated its addictive behavioral effects (at this stage ARMR-100 is not FDA-approved, human safety and efficacy have not been established, and preclinical results may not predict clinical outcomes).

Unlike reactive antidotes, this would provide months of protection – functioning like a biochemical shield.

The program is building on seven years of U.S. Department of Defense–funded research and is working to leverage proven vaccine components, such as carrier proteins already approved in licensed products and adjuvants tested in hundreds of clinical trials.

The Market and ARMR’s Mission

The potential reach is vast: 2.7 million Americans with opioid use disorder, over 2 million first responders and law enforcement officers, more than 18 million military personnel and veterans who experience higher rates of opioid use, chronic pain, and post-traumatic stress disorder, and more than 30 million high-risk young people.

A once or twice annual preventive shot could help transform national defense against fentanyl, making protection scalable across households, schools, hospitals, and security agencies.

The fentanyl crisis is no longer just a health issue – it’s a national security emergency. And we believe prevention, not rescue, may be the only path to saving a generation.

Why Investors Should Pay Attention

ARMR is more than a biotech startup – it is working to tackle America’s most urgent social and health crisis. This is a mission-driven company focused on building a preventive defense platform that could save thousands of lives each year:

$30M private raise launched
Seven years of DoD-backed research form the foundation
Lead candidate ARMR-100 blocked 92% of fentanyl from entering the brain in preclinical studies
A targeted exchange listing in the future

By investing in this round, investors have a chance to back a company whose mission is as much about impact as it is about growth potential.

Invest now to help support ARMR’s efforts to build the nation’s first line of defense against fentanyl and other synthetic threats.

For Accredited Investors Only. This offering is made pursuant to Rule 506(c) of Regulation D. All purchasers must be accredited investors, and the issuer will take reasonable steps to verify accredited status before any sale. Investing involves high risk, including the potential loss of your entire investment.

This is a paid advertisement for ARMR’s private offering. Please read the details of the offering at InvestARMR.com for additional information on the company and the risk factors related to the offering.

For investors from Canada: This advertisement forms part of the issuer’s marketing materials and is incorporated by reference into the issuer’s Offering Memorandum/Private Placement Memorandum under NI 45-106. Investors must receive and review the OM/PPM and execute the prescribed Form 45-106F4 Risk Acknowledgement before subscribing.

DISCLOSURES & DISCLAIMERS

CLIENT CONTENT: Carboncredits.com is not responsible for any content hosted on ARMR Sciences’ sites; it is ARMR Sciences’ responsibility to ensure compliance with applicable laws.

NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content should be considered promotional and subject to disclosed conflicts of interest.

Do NOT rely on this as personalized investment advice. Do your own due diligence.

Carboncredits.com strongly recommends you consult a licensed or registered professional before making any investment decision.

REGULATORY STATUS: Neither Carboncredits.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

CONTENT & COMPENSATION DISCLOSURE: Carboncredits.com has received compensation of thirty thousand dollars from ARMR Sciences for this sponsored content. You should assume we receive compensation as indicated for any purchases through links in this article via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies. We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.

RESULTS NOT TYPICAL: Past performance and results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Market conditions and individual circumstances vary significantly. Actual results will vary widely. Investing in securities is speculative and carries high risk; you may lose some, all, or possibly more than your original investment.

HIGH-RISK: Securities discussed may be highly speculative investments subject to extreme volatility, limited liquidity, and potential total loss. The Securities are suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops, it may not continue.

CAUTIONARY STATEMENT: Certain statements in this presentation (the “Presentation”) may be deemed to be “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward-looking statements. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” Forward-looking statements, which are based on the current plans, forecasts and expectations of management of ARMR Sciences Inc. (the “Company” or “ARMR Sciences”), are inherently less reliable than historical information. Forward-looking statements are subject to risks and uncertainties, including events and circumstances that may be outside our control.

Although management believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Risks and uncertainties that could cause actual results to differ materially include, without limitation, those risks identified in the Private Placement Memorandum. Forward-looking statements speak only as of the date of the document in which they are contained, and ARMR Sciences Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.

Any forward-looking financial forecasts contained in this Presentation are subject to a number of risks and uncertainties, and actual results may differ materially. You are cautioned not to place undue reliance on such forecasts. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, all such forecasts are based upon a variety of assumptions that may not be realized, and which are highly variable. Because of the number and range of the assumptions underlying any such forecasts, many of which are subject to significant uncertainties and contingencies that are beyond the reasonable control of the issuing company, many of the assumptions inevitably will not materialize and unanticipated events and circumstances may occur subsequent to the date of any financial forecast.

Disclosure: Owners, members, directors, and employees of carboncredits.com have/may have stock or option positions in any of the companies mentioned: None.

Carboncredits.com receives compensation for this publication and has a business relationship with any company whose stock(s) is/are mentioned in this article.

Additional disclosure: This communication serves the sole purpose of adding value to the research process and is for information only. Please do your own due diligence. Every investment in securities mentioned in publications of carboncredits.com involves risks that could lead to a total loss of the invested capital.

Please read our Full RISKS and DISCLOSURE here.

AI and Biodefense – Working to Stay Ahead of Synthetic Drug Threats

Jennifer L

-

October 20, 2025

0

AI and Biodefense – Working to Stay Ahead of Synthetic Drug Threats

* Disseminated on behalf of ARMR Sciences Inc.
* For Accredited Investors Only. Offered pursuant to Rule 506(c). Reasonable steps to verify accreditation will be taken before any sale.
PAID ADVERTISEMENT – SPONSORED CONTENT

Artificial intelligence (AI) is helping transform medicine, finance, and logistics. But experts warn it could also be turned against us. With advanced modeling, AI can now generate chemical blueprints at a substantially faster rate than previously available processes. As a result, National security leaders and AI thought leaders (including OpenAI’s Sam Altman), have voiced concerns that adversaries could weaponize AI to design new bioweapons.

The New Threat Landscape

Fentanyl already stands as the deadliest synthetic opioid in U.S. history, responsible for more than 220 deaths every day. But fentanyl itself is only the beginning.

Analogs like carfentanil (100x stronger), xylazine (non-opioid threat), and nitazenes (40x stronger) are beginning to spread, many of which are not reversible with Narcan.

The drug supply is becoming a testing ground for increasingly lethal compounds, some of which could be accelerated by AI-driven chemistry.

This dual challenge – lethal analogs on the street and the potential for AI-designed agents – has led federal agencies, including the Department of Defense and Homeland Security, to classify fentanyl and its cousins as chemical weapons of mass destruction.

The crisis is no longer just a health issue; it is a national security emergency.

ARMR’s Defense Labs Approach

ARMR Sciences is working to position itself to confront this next phase. Its Defense Labs initiative combines AI-powered drug discovery with seven years of Department of Defense–funded science with the goal of building a scalable biodefense platform.

The company’s lead candidate, ARMR-100, designed to train the immune system to block fentanyl before it reaches the brain. In preclinical (animal) studies, ARMR-100 blocked 92% of fentanyl’s entry into the brain and eliminated its addictive behavioral effects (at this stage ARMR-100 is not FDA-approved, human safety and efficacy have not been established, and preclinical results may not predict clinical outcomes).

Unlike reactive tools such as naloxone, ARMR-100 is designed to provide months of protection – a biochemical shield against fentanyl and, eventually, other engineered analogs.

Beyond fentanyl, ARMR plans to develop additional immunotherapies for xylazine, nitazenes, and other emerging threats, creating a portfolio that evolves alongside the risks.

By leveraging AI in its own labs, ARMR seeks to stay ahead of adversaries who might misuse the same technology. And in the battle between innovation and misuse, its proactive biodefense may prove to be America’s strongest shield.

The Scale and the Urgency

With more than 130 million people in the U.S. considered high-risk – from opioid use disorder patients to first responders and military personnel – the potential market is vast.

For policymakers, the message is clear: synthetic opioids are no longer only a health crisis, but a recognized national security threat. Classified alongside terrorism and cyberwarfare, fentanyl and its analogs demand rapid action.

This urgency is creating bipartisan momentum for federal funding, regulatory fast-tracking, and stockpiling of new countermeasures.

Why Investors Should Pay Attention

For investors, we believe that ARMR represents an opportunity to back a company that combines social impact with growth potential. Its model combines biotechnology, AI, and biodefense – a convergence few companies are addressing:

Seven years of DoD-backed research formed the platform’s foundation
Lead candidate ARMR-100 blocked 92% of fentanyl from entering the brain in preclinical studies
A $30M private raise is now open
A targeted exchange listing in the future

By investing in this round, investors have a chance to support ARMR as it works to build a category-defining role in AI-powered biodefense.

Invest now to help support ARMR’s efforts to build the nation’s first line of defense against fentanyl and other synthetic threats.

* For Accredited Investors Only. This offering is made pursuant to Rule 506(c) of Regulation D. All purchasers must be accredited investors, and the issuer will take reasonable steps to verify accredited status before any sale. Investing involves high risk, including the potential loss of your entire investment.

* This is a paid advertisement for ARMR’s private offering. Please read the details of the offering at InvestARMR.com for additional information on the company and the risk factors related to the offering.

* For investors from Canada: This advertisement forms part of the issuer’s marketing materials and is incorporated by reference into the issuer’s Offering Memorandum/Private Placement Memorandum under NI 45-106. Investors must receive and review the OM/PPM and execute the prescribed Form 45-106F4 Risk Acknowledgement before subscribing.

DISCLOSURES & DISCLAIMERS

CLIENT CONTENT: Carboncredits.com is not responsible for any content hosted on ARMR Sciences’ sites; it is ARMR Sciences’ responsibility to ensure compliance with applicable laws.

NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content should be considered promotional and subject to disclosed conflicts of interest.

Do NOT rely on this as personalized investment advice. Do your own due diligence.

Carboncredits.com strongly recommends you consult a licensed or registered professional before making any investment decision.

REGULATORY STATUS: Neither Carboncredits.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

CONTENT & COMPENSATION DISCLOSURE: Carboncredits.com has received compensation of thirty thousand dollars from ARMR Sciences for this sponsored content. You should assume we receive compensation as indicated for any purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies. We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.

RESULTS NOT TYPICAL: Past performance and results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Market conditions and individual circumstances vary significantly. Actual results will vary widely. Investing in securities is speculative and carries high risk; you may lose some, all, or possibly more than your original investment.

HIGH-RISK: Securities discussed may be highly speculative investments subject to extreme volatility, limited liquidity, and potential total loss. The Securities are suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops, it may not continue.

DISCLAIMERS & CAUTIONARY STATEMENT: Certain statements in this presentation (the “Presentation”) may be deemed to be “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward-looking statements. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” Forward-looking statements, which are based on the current plans, forecasts and expectations of management of ARMR Sciences Inc. (the “Company” or “ARMR Sciences”), are inherently less reliable than historical information. Forward-looking statements are subject to risks and uncertainties, including events and circumstances that may be outside our control.

Although management believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Risks and uncertainties that could cause actual results to differ materially include, without limitation, those risks identified in the Private Placement Memorandum. Forward-looking statements speak only as of the date of the document in which they are contained, and ARMR Sciences Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.

Any forward-looking financial forecasts contained in this Presentation are subject to a number of risks and uncertainties, and actual results may differ materially. You are cautioned not to place undue reliance on such forecasts. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, all such forecasts are based upon a variety of assumptions that may not be realized, and which are highly variable. Because of the number and range of the assumptions underlying any such forecasts, many of which are subject to significant uncertainties and contingencies that are beyond the reasonable control of the issuing company, many of the assumptions inevitably will not materialize and unanticipated events and circumstances may occur subsequent to the date of any financial forecast.

ARMR Sciences Inc. takes no responsibility for any forecasts contained within the Presentation. None of the information contained in any offering materials should be regarded as a representation by ARMR Sciences Inc. The Company’s forecasts have not been prepared with a view toward public disclosure or compliance with the guidelines of the SEC, the American Institute of Certified Public Accountants or the Public Company Accounting Oversight Board. Independent public accountants have not examined nor compiled any forecasts and have not expressed an opinion or assurance with respect to the figures.

This Presentation also contains estimates and other statistical data made by independent parties and by management relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

ARMR Sciences Inc. is currently undertaking a private placement offering of Offered Shares pursuant to Section 4(a)(2) of the 1933 Act and/or Rule 506(c) of Regulation D promulgated thereunder. Investors should consider the investment objectives, risks, and investment time horizon of the Company carefully before investing. The private placement memorandum relating to the offering of Securities will contain this and other information concerning the Company, including risk factors, which should be read carefully before investing.

The Securities are being offered and sold in reliance on exemptions from registration under the 1933 Act. In accordance therewith, you should be aware that (i) the Securities may be sold only to “accredited investors,” as defined in Rule 501 of Regulation D; (ii) the Securities will only be offered in reliance on an exemption from the registration requirements of the Securities Act and will not be required to comply with specific disclosure requirements that apply to registration under the Securities Act; (iii) the United States Securities and Exchange Commission (the “SEC”) will not pass upon the merits of or give its approval to the terms of the Securities or the offering, or the accuracy or completeness of any offering materials; (iv) the Securities will be subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities; and (v) investing in these Securities involves a high degree of risk, and investors should be able to bear the loss of their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time.

The Company is “Testing the Waters” under Regulation A under the Securities Act of 1933. The Company is not under any obligation to make an offering under Regulation A. No money or other consideration is being solicited in connection with the information provided, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until an offering statement on Form 1-A has been filed and until the offering statement is qualified pursuant to Regulation A of the Securities Act of 1933, as amended, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date.

The securities offered using Regulation A are highly speculative and involve significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards.

Tesla Rides High Before Q3 Earnings With (TSLA) Stock Rising, Record Deliveries, Gigafactory Growth, and Green Goals

Jennifer L

-

October 20, 2025

0

Tesla Rides High Before Q3 Earnings With (TSLA) Stock Rising, Record Deliveries, Gigafactory Growth, and Green Goals

Tesla, Inc. continues to show strong performance in 2025. In the third quarter alone, the company delivered 497,099 vehicles, close to half a million units. This figure is one of Tesla’s highest quarterly delivery totals on record. At the same time, its Austin Gigafactory reached a key production milestone — more than 500,000 vehicles built since opening in 2022.

These achievements confirm Tesla’s steady expansion of its manufacturing network. The company now runs major factories in California, Texas, Nevada, Germany, and China. Each plant contributes to a growing global supply chain that supports its Model Y, Model 3, and the new Cybertruck.

Tesla’s steady ramp-up shows how far it has come since its early production struggles. The company aims to reach 20 million vehicles a year by 2030. This plan is ambitious, but this quarter’s numbers show steady progress toward that goal.

Gigafactory Texas Reaches a Key Milestone

Gigafactory Texas, near Austin, is Tesla’s biggest and most advanced U.S. facility. It makes the Model Y and is ramping up Cybertruck production. Hitting 500,000 vehicles in roughly three and a half years shows faster growth compared to Tesla’s earlier plants.

Reports say around 100,000 vehicles were made from April to mid-October 2025. This strong pace helps meet annual growth targets. The plant uses Giga Presses, which are massive casting machines that replace dozens of smaller parts. This automation speeds up production, reduces costs, and minimizes material waste.

The Texas facility also plays a central role in Tesla’s sustainability strategy. Much of its electricity comes from renewable energy, and its design reduces water use and waste. Over time, Tesla aims for all Gigafactories to operate with 100% clean energy.

Q3 Earnings Outlook: Revenue Growth, Margin Pressure

Analysts expect Tesla to post around $26.3 billion in revenue for Q3 2025, up about 4–5% year-over-year. However, earnings per share (EPS) are projected to fall about 24%, to roughly $0.55 per share from $0.72 in the same quarter last year.

The decline is mainly due to lower vehicle prices and smaller contributions from carbon redit sales. These credits have been providing a huge revenue stream to the EV giant by selling it to its peers that don’t meet regulatory emission reductions.

Also, Tesla has cut prices on its main models in several markets to stay competitive, especially against Chinese EV makers. Those price cuts attract new buyers but reduce profit margins.

Tesla’s operating margin averaged 9.2% in Q2 2025, down from 11.4% a year earlier. Automotive gross margin, excluding credits, was about 18%, compared to over 25% in 2022. Even with tighter margins, Tesla continues to benefit from software revenue through Full Self-Driving (FSD) packages and connectivity subscriptions.

The company’s results will likely depend on several key factors:

Vehicle deliveries – nearly half a million this quarter.
Energy storage deployments – reaching a new record of 12.5 GWh.
Software and services – providing recurring, higher-margin income.
Production costs – influenced by logistics and raw material expenses.

Despite margin pressure, Tesla’s growth in energy storage and software could offset some of the decline in car profits.

The Global EV Race Accelerates

The global electric vehicle (EV) market continues to expand rapidly. The International Energy Agency (IEA) reports that global EV sales rose over 30% in 2024. They reached almost 14 million units. In 2025, sales could hit 17 million. Electric cars could represent about 22% of all vehicle sales globally by the end of this year.

Tesla remains a market leader, holding around 16% of global EV market share, but it faces rising competition. Chinese brands like BYD, NIO, and XPeng are growing in Asia and Europe. At the same time, Volkswagen, Ford, GM, and Hyundai are speeding up EV production.

Elon Musk’s company defends its position by improving efficiency and cutting costs. Its 4680 battery cells are key, aiming to lower production costs by up to 50%. They also enhance range and durability.

The company also benefits from the U.S. Inflation Reduction Act (IRA), which offers tax credits for EV buyers and incentives for battery production. However, these credits will gradually phase out, which could affect demand after 2026.

According to BloombergNEF, the average price of lithium-ion batteries dropped to $115 per kWh in 2024, down 20% from 2023. This decline helps Tesla maintain affordability while protecting margins.

Wall Street Takes the Wheel: Tesla Stock Gains on Big Deliveries

Tesla’s stock rose modestly after its Q3 delivery report. On Monday, shares gained, surpassing $444, which doubled in six months. The rise reflects investor confidence in Tesla’s production capacity and delivery strength, even with profit pressure.

Analysts remain split: some expect stronger earnings in 2026 as new models roll out, while others warn that price cuts and competition could slow growth.

Still, Tesla’s ability to maintain high output while scaling its energy business supports its long-term outlook. The company is a top choice for big investors like BlackRock and Vanguard. They both focus on sustainability in their investment strategies.

SEE MORE: Tesla (TSLA) Stock Rises Over $450, Hits Record $1.5T Market Cap as Q3 Delivery Test Looms

Driving Clean: Tesla’s Growing Role in a Net-Zero World

Tesla’s business model directly supports global emission-reduction goals. Tesla’s 2024 Impact Report shows that customers avoided almost 32 million metric tons of CO₂e emissions. This is a 60% increase from last year. This figure includes emissions avoided by Tesla’s vehicles as well as its solar and energy storage products globally.

Since 2012, Tesla’s fleet has avoided many millions of metric tons of CO₂e. Each vehicle saves about 52 metric tons of CO₂e compared to similar gasoline cars over an average lifespan of 17 years.

Tesla also focuses on sustainable manufacturing:

Gigafactory Nevada recycles more than 92% of production waste and reduces its water use intensity by 12% year-over-year.
The company sources lithium and aluminum from suppliers following responsible mining and low-carbon standards.
Its battery recycling program recovers up to 95% of nickel, cobalt, and lithium for reuse.

Beyond vehicles, Tesla’s energy business is expanding fast. In 2024, the company deployed 15 GWh of energy storage through its Megapack and Powerwall systems — enough to power over 4 million homes for one hour. These systems help utilities store renewable energy, stabilize grids, and reduce fossil fuel reliance.

Tesla aims to reach net-zero emissions across its value chain by 2040, covering factories, logistics, and product lifecycles. Investments in solar, wind, and carbon reduction projects are key to that goal.

Roadblocks and Roadmaps: What’s Next for Tesla

Amid its strong momentum, Tesla still faces several challenges that could affect future growth:

Competition: Rivals are narrowing the gap in technology and cost.
Price pressure: Discounts to boost demand reduce profitability.
Regulatory risks: Autopilot and FSD remain under scrutiny in some markets.
Supply chain: Securing critical minerals like lithium and nickel remains essential.

To adapt, Tesla is diversifying. The company plans to launch a low-cost compact vehicle, often referred to as the Model 2, expected to be priced under $27,000 and launched in late 2026.

It’s also developing a robotaxi platform, codenamed CyberCab, expected to begin pilot operations in 2026 with Level 4 autonomy. Plus, Tesla Energy could exceed $10 billion in annual revenue by 2026, supported by growing Megapack demand in the U.S. and Europe.

RELATED: Tesla Robotaxi Secures Permit in Texas, Fuels TSLA Stock Surge and Market Buzz

Tesla’s Q3 2025 milestones highlight both progress and pressure. Delivering nearly 500,000 vehicles and producing 500,000 at its Texas plant shows major strides in sustainable mobility. Revenue continues to grow even as profits tighten.

As Tesla prepares to announce its Q3 earnings, investors will look for signs of balance — growth, profitability, and sustainability. If the company keeps expanding responsibly and investing in cleaner technologies, it will remain a central player in the global transition toward a zero-emission economy.

READ MORE: Tesla Shifts From EVs to AI: Musk Says Robots Will be 80% of Company Value

Fentanyl Threats, AI, and National Security – ARMR Sciences’ Unified Approach

Jennifer L

-

October 20, 2025

0

Fentanyl Threats, AI, and National Security – ARMR Sciences’ Unified Approach

* Disseminated on behalf of ARMR Sciences Inc.
* For Accredited Investors Only. Offered pursuant to Rule 506(c). Reasonable steps to verify accreditation will be taken before any sale.
PAID ADVERTISEMENT – SPONSORED CONTENT

Fentanyl is devastating American communities at a record pace, with more than 220 deaths every day. Synthetic opioids accounted for over 70,000 U.S. fatalities in 2023, and their impact now extends beyond public health into national security.

At the same time, artificial intelligence (AI) is advancing in ways that could allow adversaries to design new synthetic drugs or bioweapons faster than regulators and security agencies can respond. Coupled with the political weight fentanyl carries in Washington, the U.S. faces a multidimensional challenge.

ARMR Sciences underscores why prevention, innovation, and leadership can align to shield America from this emerging and evolving threat.

Escalating National Security Concerns

Fentanyl’s extraordinary potency – up to 50 times stronger than heroin – makes even trace exposure lethal. Its supply chains cross borders, complicating law enforcement and fueling instability at home.

ARMR Sciences emphasizes that enforcement alone cannot resolve the crisis. Without proactive prevention strategies, the nation risks a deepening cycle of addiction, death, and weakened resilience.

Technology at the Crossroads

AI has the potential to transform healthcare and logistics, but also carries risks of misuse. Researchers showed that advanced AI models could generate tens of thousands of psychoactive compound blueprints in just hours – a dangerous acceleration of synthetic chemistry.

National security leaders, including AI pioneers, warn that adversaries could exploit these tools. ARMR Sciences argues for robust biodefense strategies that include strict controls on sensitive algorithms, enhanced detection systems, and proactive investment in prevention technologies.

Political Pressure and Policy Response

The fentanyl crisis has become a defining issue in U.S. politics, shaping debates on border security, healthcare, and law enforcement funding. Deaths have risen by more than 20% annually since 2019, amplifying public and political demands for action.

ARMR Sciences emphasizes that bipartisan cooperation and evidence-based policymaking are essential to prevent partisan gridlock. Recognizing fentanyl as both a health and security issue can unite leaders behind more effective prevention measures.

ARMR Sciences – A Prevention-Focused Framework

Across each dimension – fentanyl’s deadly toll, AI’s potential misuse, and the political battle for solutions – ARMR Sciences underscores a common theme: prevention is the most effective defense. This means deploying early warning systems, advancing detection capabilities, integrating data-driven tools, and strengthening community resilience before crises escalate.

It also means ensuring that AI innovation develops with responsible guardrails, while national security agencies adapt to evolving synthetic threats. Prevention is not passive; it requires deliberate action, investment, and leadership.

So, Why Should Investors Pay Attention to ARMR’s Solution?

For investors, ARMR represents an opportunity to back a company working to address the convergence of fentanyl’s deadly impact, AI’s potential misuse, and the urgent need for prevention.

Its platform is built on years of defense-backed research and is advancing innovative biotechnology programs:

Seven years of DoD-supported science established the foundation of ARMR’s platform
Lead candidate ARMR-100 blocked 92% of fentanyl from entering the brain in preclinical (animal) studies
A $30M private raise is currently underway
Plans for a targeted exchange listing in 2026 are in place, subject to market conditions

By investing in this round, investors have a chance to support ARMR as it works to build a potentially category-defining role in AI-powered biodefense.

* This is a paid advertisement for ARMR’s private offering. Please read the details of the offering at InvestARMR.com for additional information on the company and the risk factors related to the offering.

* For Accredited Investors Only. This offering is made pursuant to Rule 506(c) of Regulation D. All purchasers must be accredited investors, and the issuer will take reasonable steps to verify accredited status before any sale. Investing involves high risk, including the potential loss of your entire investment.

* For investors from Canada: This advertisement forms part of the issuer’s marketing materials and is incorporated by reference into the issuer’s Offering Memorandum/Private Placement Memorandum under NI 45-106. Investors must receive and review the OM/PPM and execute the prescribed Form 45-106F4 Risk Acknowledgement before subscribing.

DISCLOSURES & DISCLAIMERS

CLIENT CONTENT: Carboncredits.com is not responsible for any content hosted on ARMR Sciences’ sites; it is ARMR Sciences’ responsibility to ensure compliance with applicable laws.

NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content should be considered promotional and subject to disclosed conflicts of interest.

Do NOT rely on this as personalized investment advice. Do your own due diligence.

Carboncredits.com strongly recommends you consult a licensed or registered professional before making any investment decision.

REGULATORY STATUS: Neither Carboncredits.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

CONTENT & COMPENSATION DISCLOSURE: Carboncredits.com has received compensation of thirty thousand dollars from ARMR Sciences for this sponsored content. You should assume we receive compensation as indicated for any purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies. We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.

RESULTS NOT TYPICAL: Past performance and results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Market conditions and individual circumstances vary significantly. Actual results will vary widely. Investing in securities is speculative and carries high risk; you may lose some, all, or possibly more than your original investment.

HIGH-RISK: Securities discussed may be highly speculative investments subject to extreme volatility, limited liquidity, and potential total loss. The Securities are suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops, it may not continue.

CAUTIONARY STATEMENT: Certain statements in this presentation (the “Presentation”) may be deemed to be “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward-looking statements. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” Forward-looking statements, which are based on the current plans, forecasts and expectations of management of ARMR Sciences Inc. (the “Company” or “ARMR Sciences”), are inherently less reliable than historical information. Forward-looking statements are subject to risks and uncertainties, including events and circumstances that may be outside our control.